Ken Greenberg, SonoThera CEO

Gene ther­a­py goes acoustic as ARCH-backed biotech launch­es with ul­tra­sound gene de­liv­ery plat­form

Af­ter co-found­ing two biotechs off virus-based ther­a­pies, one for pain and one for can­cer, Ken Green­berg de­cid­ed to go in a dif­fer­ent di­rec­tion for his newest biotech, SonoThera.

Based out of San Fran­cis­co, SonoThera an­nounced Mon­day morn­ing that it raised $60.75 mil­lion to de­vel­op new gene ther­a­pies — but de­liv­ered by ul­tra­sound, which Green­berg says can ad­dress the ma­jor chal­lenges fac­ing more con­ven­tion­al vi­ral gene ther­a­pies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.